Core Viewpoint - Cyclacel Pharmaceuticals, Inc. is implementing a 1-for-15 reverse stock split effective July 7, 2025, to enhance its stock price and maintain compliance with Nasdaq listing requirements [1][3]. Company Overview - Cyclacel is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines based on cell cycle, epigenetics, and mitosis biology [4]. - The company is evaluating plogosertib, a PLK1 inhibitor, in patients with solid tumors and hematological malignancies as part of its epigenetic/anti-mitotic program [4]. - Cyclacel aims to build a diversified biopharmaceutical business with a pipeline of novel drug candidates targeting oncology and hematology indications [4]. Reverse Stock Split Details - The reverse stock split will convert every 15 shares of common stock into one share, with no fractional shares issued; any fractions will be rounded to the nearest whole number [2]. - The board of directors and stockholders approved the reverse stock split, which will reduce the number of shares from 23,759,475 to 1,583,965 [3]. - The new CUSIP number for the shares post-split will be 23254L876, and trading will continue under the symbol "CYCC" on The Nasdaq Capital Market [1][3].

Core Viewpoint - Boqii Holding Limited will terminate its Deposit Agreement and implement a reverse stock split, consolidating every 160 ordinary shares into one new ordinary share, with plans to list its Class A ordinary shares on NYSE American LLC [1][2] Company Actions - The termination of the Deposit Agreement was approved by shareholders on June 26, 2025 [1] - A reverse stock split will occur, consolidating every 160 ordinary shares into one new ordinary share [1] - The company plans to list its Class A ordinary shares on NYSE American LLC, replacing the American depositary shares (ADSs) [2] Company Overview - Boqii Holding Limited is a leading pet-focused platform in China, offering a wide selection of high-quality pet products [3] - The company provides products from global leading brands, local emerging brands, and its own private labels, including Yoken, Mocare, and D-cat [3] - Boqii's online sales platforms include Boqii Mall and flagship stores on third-party e-commerce platforms, enhancing customer access and shopping experience [3]

Core Points - The company announced a 1-for-15 reverse stock split effective July 3, 2025, to comply with Nasdaq's minimum bid price requirement [1][2] - The reverse stock split will reduce the number of outstanding shares from approximately 41,492,767 to about 2,766,185 shares [4] - The company entered into a Forbearance Agreement with Bank of America on June 23, 2025, providing additional time to pursue alternative debt financing options [5] Reverse Stock Split Details - The reverse stock split will combine every fifteen shares into one share without changing the par value [3] - No fractional shares will be issued; stockholders will receive whole shares rounded up [3] - The authorized shares will remain unchanged at 250,000,000 shares [4] Forbearance Agreement Insights - The Forbearance Agreement will expire upon the occurrence of certain events, including any Event of Default or breach of the agreement [5] - The company has received two bona fide term sheets from reputable financial institutions for a potential refinancing transaction [5]

Core Viewpoint - Super League Enterprise, Inc. announced a reverse stock split at a ratio of 1-for-40 to comply with Nasdaq's minimum bid price requirement for continued listing [1][4]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 AM on June 23, 2025, with shares trading on a split-adjusted basis on the same day [2]. - The number of outstanding shares will decrease from approximately 35.4 million to about 884 thousand shares following the split [3]. - Each stockholder's percentage ownership and voting power will remain largely unchanged, with fractional shares rounded up to the nearest whole share [5]. Group 2: Compliance and Listing - The reverse split is a response to a deficiency notice from Nasdaq regarding the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) [4]. - The company aims to regain compliance with Nasdaq's continued listing standards through this action [9]. Group 3: Company Overview - Super League is a leader in engaging audiences through playable media and experiences within mobile games and immersive platforms [7]. - The company provides global brands with interactive ads and content, enhancing consumer engagement and brand loyalty [7].

Core Viewpoint - Unicycive Therapeutics, Inc. is implementing a 1-for-10 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective June 18, 2025, with trading on a split-adjusted basis starting June 20, 2025 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will combine every ten shares into one, reducing the number of issued shares from approximately 126,409,281 to about 12,640,929 [4]. - Stockholders will not receive fractional shares; instead, fractional interests will be rounded up to the next whole share [3]. - The reverse stock split will not affect stockholders' percentage ownership or voting power, except for minor changes due to fractional shares [3]. Group 2: Compliance and Adjustments - The reverse stock split aims to increase the bid price of the common stock to meet the $1.00 minimum bid price requirement for continued listing on Nasdaq [2]. - Proportionate adjustments will be made to the exercise prices and number of shares underlying stock options, warrants, and preferred stock as a result of the reverse stock split [5]. Group 3: Company Overview - Unicycive Therapeutics is focused on developing therapies for kidney diseases, with its lead investigational treatment, oxylanthanum carbonate, under FDA review for treating hyperphosphatemia in chronic kidney disease patients on dialysis [8]. - The second investigational treatment, UNI-494, is aimed at conditions related to acute kidney injury and has received orphan drug designation from the FDA [9].

KULR Technology (KULR -21.53%) stock is getting hit with huge selling action in Monday's trading. The company's share price was down 21.3% as of 3 p.m. ET, despite the S&P 500 (^GSPC 0.82%) being up 0.9% at the same point in the day's trading.KULR is seeing a big valuation pullback today following news that the company will carry out a reverse stock split. The new structure for the stock won't do anything to alter the fundamentals of the business, but investors are dumping shares ahead of the 8-for-1 revers ...

Core Viewpoint - Onconetix, Inc. has received approval from the Nasdaq Hearings Panel for continued listing on The Nasdaq Stock Market, contingent upon compliance with specific Nasdaq Listing Rules by set deadlines [1][2]. Group 1: Compliance and Listing Status - On June 11, 2025, Onconetix was granted a decision for continued listing, requiring compliance with the Periodic Filing Listing Rule by June 13, 2025, and the Bid Price Listing Rule by June 30, 2025 [1]. - The company demonstrated compliance with the Periodic Filing Listing Rule on June 12, 2025, by filing the Form 10-Q for the period ended March 31, 2025 [2]. - A 1-for-85 reverse stock split of its outstanding shares was completed on June 13, 2025, to help meet listing requirements [2]. Group 2: Company Overview - Onconetix, Inc. is a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology [3]. - The company owns Proclarix, an in vitro diagnostic test for prostate cancer, which is approved for sale in the European Union [3].

Core Viewpoint - RAPT Therapeutics, Inc. announced a 1-for-8 reverse stock split effective June 16, 2025, aimed at consolidating its outstanding shares to potentially enhance its stock price and market perception [1][2]. Company Overview - RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunological diseases [5]. Reverse Stock Split Details - The reverse stock split will reduce the number of issued and outstanding shares from approximately 132.3 million to approximately 16.5 million [4]. - The reverse stock split will be effective at 11:59 pm Eastern Time on June 16, 2025, with trading on a reverse stock split-adjusted basis starting June 17, 2025 [1][2]. - Every eight issued and outstanding shares will be combined into one share without changing the par value per share, and fractional shares will not be issued [3]. - Stockholders entitled to fractional shares will receive a cash payment instead [3]. - The total number of authorized shares will remain at 500 million, but the number available for future issuance will increase [3]. Impact on Stockholders - The reverse stock split will affect all stockholders uniformly and will not alter their relative interest in the company's equity securities, except for adjustments related to fractional shares [3].

Group 1 - Shuttle Pharmaceuticals Holdings, Inc. will implement a reverse stock split effective June 16, 2025, at 12:01 a.m. Eastern Time, with the common stock continuing to trade under the symbol "SHPH" on Nasdaq [1][2] - The reverse stock split will convert every 25 shares of the Company's common stock into 1 share, reducing the total number of outstanding shares from approximately 26,210,037 to about 1,048,401 shares [2] - This action is part of Shuttle's strategic plan to comply with Nasdaq's continued listing requirements and to strengthen the Company's long-term capital structure [3] Group 2 - Shuttle Pharmaceuticals is focused on improving outcomes for cancer patients undergoing radiation therapy by developing therapies that enhance the effectiveness of radiation while minimizing side effects [4] - The Company aims to increase cancer cure rates, prolong patient survival, and improve quality of life through the development of radiation sensitizers, which can be used alone or in combination with other treatments [4]

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has announced a proposed reverse stock split of its common stock at a ratio of 25-for-1, subject to Nasdaq approval, aimed at maintaining compliance with listing requirements and strengthening its capital structure [1][3]. Group 1: Reverse Stock Split Details - At the effective time of the reverse stock split, every 25 shares of the Company's common stock will be combined into 1 share, reducing the total number of shares from 26,210,037 to approximately 1,048,401 shares [2]. - The reverse stock split will also apply to common stock issuable upon the exercise of outstanding RSU grants and warrants, with no fractional shares issued; fractional entitlements will be rounded up to the next highest whole number [2]. Group 2: Company Overview - Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy [4]. - The Company's mission is to enhance the effectiveness of radiation therapy while minimizing side effects, aiming to increase cancer cure rates, prolong patient survival, and improve quality of life [4].